文献速递肿瘤 PET/CT

AUTO-PERCIST™量化[18F]FDG PET/CT肿瘤治疗反应的多中心测量变异性评估

Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™.
PubMed 文献 · EJNMMI Res · 2021-02-12

该多中心研究评估了使用同一半自动软件AUTO-PERCIST™定量分析癌症患者治疗前后[18F]FDG PET/CT图像时读者间的变异性。30例肿瘤患者的配对图像由13名读者分析,最热肿瘤SULpeak变化百分比的ICC为0.87(95%CI 0.78-0.92),当读者选择与参考读者相同的目标肿瘤时ICC为1.00。基于PERCIST 1.0的代谢反应评估Krippendorff alpha系数为0.91,相同靶病灶选择时为1.00。

要点

  • 使用同一软件AUTO-PERCIST™时,多中心读者间最热肿瘤SULpeak变化百分比的ICC达0.87。
  • 当读者选择相同目标肿瘤时,SULpeak变化百分比的ICC为1.00,反应分类alpha系数为1.00。
  • 基于PERCIST 1.0的代谢反应分类在所有读数中Krippendorff alpha为0.91。

核心结论

  • 多中心、多读者使用AUTO-PERCIST™测量的肿瘤[18F]FDG SULpeak变化呈现高度相关性。
  • 当读者选择相同目标肿瘤时,软件提取的定量治疗反应数据几乎完全一致。

研究设计与样本

  • 研究纳入30例肿瘤患者的治疗前后配对[18F]FDG PET/CT图像,使用AUTO-PERCIST™半自动软件进行分析。
  • 13名来自美国及国际站点的读者参与,其中1名参考读者知晓患者病史,其余12名读者对病史盲法但可获取相关图像。

主要发现

  • 所有读数(n=297)中最热肿瘤SULpeak变化百分比的ICC为0.87(95%CI 0.78-0.92)。
  • 仅纳入与参考读者选择相同目标肿瘤的测量(n=224)时,SULpeak变化百分比的ICC为1.00(95%CI 1.00-1.00)。
  • 基于PERCIST 1.0的代谢反应分类(完全或部分代谢反应 vs 稳定或进展性代谢疾病)Krippendorff alpha系数在所有读数(n=380)中为0.91,相同目标肿瘤选择时(n=270)为1.00。

关键数值与推荐

  • AUTO-PERCIST™自动识别肝脏并计算肿瘤可测量阈值:(1.5×肝脏平均值)+(2×肝脏标准差),然后检测SULpeak高于阈值的所有部位。
  • 主要评价指标为基线和随访图像上识别的最热肿瘤的SULpeak变化百分比(%ΔSULpeak)。
  • 反应分类依据PERCIST 1.0标准,分为完全或部分代谢反应 vs 稳定或进展性代谢疾病。

临床怎么用

  • 在多个国际站点和读者间使用统一软件AUTO-PERCIST™可获得高度一致的肿瘤[18F]FDG SULpeak变化定量数据。
  • 读者选择相同目标肿瘤时定量治疗反应数据几乎完全相同,提示统一软件和方法有助于减少测量变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to assess the reader variability in quantitatively assessing pre- and post-treatment 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) scans in a defined set of images of cancer patients using the same semi-automated analytical software (Auto-PERCIST™), which identifies tumor peak standard uptake value corrected for lean body mass (SULpeak) to determine [18F]FDG PET quantitative parameters. METHODS: Paired pre- and post-treatment [18F]FDG PET/CT images from 30 oncologic patients and Auto-PERCIST™ semi-automated software were distributed to 13 readers across US and international sites. One reader was aware of the relevant medical history of the patients (readreference), whereas the 12 other readers were blinded to history but had access to the correlative images. Auto-PERCIST™ was set up to first automatically identify the liver and compute the threshold for tumor measurability (1.5 × liver mean) + (2 × liver standard deviation [SD]) and then detect all sites with SULpeak greater than the threshold. Next, the readers selected sites they believed to represent tumor lesions. The main performance metric assessed was the percent change in the SULpeak (%ΔSULpeak) of the hottest tumor identified on the baseline and follow-up images. RESULTS: The intra-class correlation coefficient (ICC) for the %ΔSULpeak of the hottest tumor was 0.87 (95%CI: [0.78, 0.92]) when all reads were included (n = 297). Including only the measurements that selected the same target tumor as the readreference (n = 224), the ICC for %ΔSULpeak was 1.00 (95%CI: [1.00, 1.00]). The Krippendorff alpha coefficient for response (complete or partial metabolic response, versus stable or progressive metabolic disease on PET Response Criteria in Solid Tumors 1.0) was 0.91 for all reads (n = 380) and 1.00 including for reads with the same target tumor selection (n = 270). CONCLUSION: Quantitative tumor [18F]FDG SULpeak changes measured across multiple global sites and readers utilizing Auto-PERCIST™ show very high correlation. Harmonization of methods to single software, Auto-PERCIST™, resulted in virtually identical extraction of quantitative tumor response data from [18F]FDG PET images when the readers select the same target tumor.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. O JH, Lim SJ, Wang H, et al. Quantitation of cancer treatment response by 2-[18F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™. EJNMMI Res. 2021. PMID: 33580383. doi:10.1186/s13550-021-00754-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。